C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity.
Journal ArticleDOI
Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure.
TL;DR: In uremia, retention of IL-18BP does not suffice to neutralize most of the concomitantly raised levels of totalIL-18 resulting in elevated levels of free IL- 18, and suppression of IFNgamma production in uremIA may be due to inhibitors of IFngammaProduction other than IL-17BP.
Journal ArticleDOI
Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine.
Edward E. Telzak,Sheldon M. Wolff,Charles A. Dinarello,Thomas Conlon,Aziz El Kholy,Gorges M. Bahr,Jean Choay,Andre Morin,Louis Chedid +8 more
Journal ArticleDOI
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
J. S. Du Bois,Elizabeth Trehu,James W. Mier,Leland Shapiro,Mark P. Epstein,Mark S. Klempner,Charles A. Dinarello,K Kappler,L Ronayne,William M. Rand,Michael B. Atkins +10 more
TL;DR: Despite evidence of in vitro neutralization of TNF functional activity and partial inhibition of other secondary biologic effects of IL-2, rhuTNFR:Fc does not reduce the clinical toxicity associated with high-dose IL- 2 therapy.
Journal ArticleDOI
Extracellular superoxide dismutase haplotypes are associated with acute lung injury and mortality.
John J. Arcaroli,John E. Hokanson,Edward Abraham,Mark W. Geraci,James Murphy,Russell P. Bowler,Charles A. Dinarello,Lori J. Silveira,Jeffrey Sankoff,Daren K. Heyland,Paul E. Wischmeyer,James D. Crapo +11 more
TL;DR: Results indicate that a GCCT haplotype may reduce inflammation in the lung, thereby decreasing the severity of lung injury and ultimately protecting patients from mortality associated with infection-induced ALI.